European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines
The European Medicines Agency has reviewed further data on the centrally authorised pandemic vaccines, Celvapan, Focetria and Pandemrix. The Agency has reaffirmed their positive balance of benefits and risks in the context of the current H1N1 influenza pandemic.
Read more: European Medicines Agency
